Telmisartan protects against diabetic vascular complications in a mouse model of obesity and type 2 diabetes, partially through peroxisome proliferator activated receptor-γ-dependent activity

Biochemical and Biophysical Research Communications

Volumn 410, Issue 3, 2011, Pages 508-513

  Toyama, Kensuke ^a   Nakamura, Taishi ^a   Kataoka, Keiichiro ^a   Yasuda, Osamu ^b   Fukuda, Masaya ^a   Tokutomi, Yoshiko ^a   Dong, Yi Fei ^a   Ogawa, Hisao ^a   Kim Mitsuyama, Shokei ^a  

^a KUMAMOTO UNIVERSITY   (Japan)

^b KUMAMOTO UNIVERSITY HOSPITAL   (Japan)

Author keywords

ARB; Diabetes; Endothelial function; ENOS; NF B; PPAR

Indexed keywords

2 CHLORO 5 NITROBENZANILIDE; ENDOTHELIAL NITRIC OXIDE SYNTHASE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; LOSARTAN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PROTEIN KINASE B; TELMISARTAN; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLOOD PRESSURE; BLOOD VESSEL INJURY; CELL INFILTRATION; CONTROLLED STUDY; CORONARY ARTERY; DIABETIC ANGIOPATHY; DRUG EFFECT; ENZYME PHOSPHORYLATION; MACROPHAGE; MALE; METABOLIC PARAMETERS; MOUSE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OBESITY; ORGAN WEIGHT; PRIORITY JOURNAL; RECEPTOR DOWN REGULATION; VASCULAR ENDOTHELIUM;

ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANILIDES; ANIMALS; BENZIMIDAZOLES; BENZOATES; DIABETES MELLITUS, TYPE 2; DIABETIC ANGIOPATHIES; DISEASE MODELS, ANIMAL; MALE; MICE; MICE, INBRED C57BL; OBESITY; PPAR GAMMA;

MUS;

EID: 79960058644     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2011.06.012     Document Type: Article

References (24)

1. Gami A.S., Witt B.J., Howard D.E., Erwin P.J., Gami L.A., Somers V.K., Montori V.M. Metabolic syndrome and risk of incident cardiovascular events and death: a systematic review and meta-analysis of longitudinal studies. J. Am. Coll. Cardiol. 2007, 49:403-414.
2. Sowers J.R., Epstein M., Frohlich E.D. Diabetes, hypertension, and cardiovascular disease: an update. Hypertension 2001, 37:1053-1059.
3. Verdecchia P., Reboldi G., Angeli F., Borgioni C., Gattobigio R., Filippucci L., Norgiolini S., Bracco C., Porcellati C. Adverse prognostic significance of new diabetes in treated hypertensive subjects. Hypertension 2004, 43:963-969.
4. Andraws R., Brown D.L. Effect of inhibition of the renin-angiotensin system on development of type 2 diabetes mellitus (meta-analysis of randomized trials). Am. J. Cardiol. 2007, 99:1006-1012.
5. Mancia G., De Backer G., Dominiczak A., Cifkova R., Fagard R., Germano G., Grassi G., Heagerty A.M., Kjeldsen S.E., Laurent S., Narkiewicz K., Ruilope L., Rynkiewicz A., Schmieder R.E., Boudier H.A., Zanchetti A. 2007 ESH-ESC practice guidelines for the management of arterial hypertension: ESH-ESC task force on the management of arterial hypertension. J. Hypertens. 2007, 25:1751-1762.
6. Hsueh W.A., Bruemmer D. Peroxisome proliferator-activated receptor gamma: implications for cardiovascular disease. Hypertension 2004, 43:297-305.
7. Pascual G., Fong A.L., Ogawa S., Gamliel A., Li A.C., Perissi V., Rose D.W., Willson T.M., Rosenfeld M.G., Glass C.K. A SUMOylation-dependent pathway mediates transrepression of inflammatory response genes by PPAR-gamma. Nature 2005, 437:759-763.
8. Benson S.C., Pershadsingh H.A., Ho C.I., Chittiboyina A., Desai P., Pravenec M., Qi N., Wang J., Avery M.A., Kurtz T.W. Identification of telmisartan as a unique angiotensin II receptor antagonist with selective PPARgamma-modulating activity. Hypertension 2004, 43:993-1002.
9. Kurtz T.W. Beyond the classic angiotensin-receptor-blocker profile. Nat. Clin. Pract. Cardiovasc. Med. 2008, 5(Suppl. 1):S19-26.
10. Schupp M., Clemenz M., Gineste R., Witt H., Janke J., Helleboid S., Hennuyer N., Ruiz P., Unger T., Staels B., Kintscher U. Molecular characterization of new selective peroxisome proliferator-activated receptor gamma modulators with angiotensin receptor blocking activity. Diabetes 2005, 54:3442-3452.
11. Schupp M., Janke J., Clasen R., Unger T., Kintscher U. Angiotensin type 1 receptor blockers induce peroxisome proliferator-activated receptor-gamma activity. Circulation 2004, 109:2054-2057.
12. Sugimoto K., Kazdova L., Qi N.R., Hyakukoku M., Kren V., Simakova M., Zidek V., Kurtz T.W., Pravenec M. Telmisartan increases fatty acid oxidation in skeletal muscle through a peroxisome proliferator-activated receptor-gamma dependent pathway. J. Hypertens. 2008, 26:1209-1215.
13. Sugimoto K., Qi N.R., Kazdova L., Pravenec M., Ogihara T., Kurtz T.W. Telmisartan but not valsartan increases caloric expenditure and protects against weight gain and hepatic steatosis. Hypertension 2006, 47:1003-1009.
14. Dormandy J.A., Charbonnel B., Eckland D.J., Erdmann E., Massi-Benedetti M., Moules I.K., Skene A.M., Tan M.H., Lefebvre P.J., Murray G.D., Standl E., Wilcox R.G., Wilhelmsen L., Betteridge J., Birkeland K., Golay A., Heine R.J., Koranyi L., Laakso M., Mokan M., Norkus A., Pirags V., Podar T., Scheen A., Scherbaum W., Schernthaner G., Schmitz O., Skrha J., Smith U., Taton J. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial. Lancet 2005, 366:1279-1289.
15. Mazzone T., Meyer P.M., Feinstein S.B., Davidson M.H., Kondos G.T., D'Agostino R.B., Perez A., Provost J.C., Haffner S.M. Effect of pioglitazone compared with glimepiride on carotid intima-media thickness in type 2 diabetes: a randomized trial. JAMA 2006, 296:2572-2581.
16. Nissen S.E., Nicholls S.J., Wolski K., Nesto R., Kupfer S., Perez A., Jure H., De Larochelliere R., Staniloae C.S., Mavromatis K., Saw J., Hu B., Lincoff A.M., Tuzcu E.M. Comparison of pioglitazone vs glimepiride on progression of coronary atherosclerosis in patients with type 2 diabetes: the PERISCOPE randomized controlled trial. JAMA 2008, 299:1561-1573.
17. Wilcox R., Bousser M.G., Betteridge D.J., Schernthaner G., Pirags V., Kupfer S., Dormandy J. Effects of pioglitazone in patients with type 2 diabetes with or without previous stroke: results from PROactive (PROspective pioglitAzone Clinical Trial In macroVascular Events 04). Stroke 2007, 38:865-873.
18. Li A.C., Brown K.K., Silvestre M.J., Willson T.M., Palinski W., Glass C.K. Peroxisome proliferator-activated receptor gamma ligands inhibit development of atherosclerosis in LDL receptor-deficient mice. J. Clin. Invest. 2000, 106:523-531.
19. Mehta J.L., Hu B., Chen J., Li D. Pioglitazone inhibits LOX-1 expression in human coronary artery endothelial cells by reducing intracellular superoxide radical generation. Arterioscler. Thromb. Vasc. Biol. 2003, 23:2203-2208.
20. Nakamura T., Yamamoto E., Kataoka K., Yamashita T., Tokutomi Y., Dong Y.F., Matsuba S., Ogawa H., Kim-Mitsuyama S. Pioglitazone exerts protective effects against stroke in stroke-prone spontaneously hypertensive rats, independently of blood pressure. Stroke 2007, 38:3016-3022.
21. Fukuda M., Nakamura T., Kataoka K., Nako H., Tokutomi Y., Dong Y.F., Ogawa H., Kim-Mitsuyama S. Potentiation by candesartan of protective effects of pioglitazone against type 2 diabetic cardiovascular and renal complications in obese mice. J. Hypertens. 2010, 28:340-352.
22. Nakamura T., Yamamoto E., Kataoka K., Yamashita T., Tokutomi Y., Dong Y.F., Matsuba S., Ogawa H., Kim-Mitsuyama S. Beneficial effects of pioglitazone on hypertensive cardiovascular injury are enhanced by combination with candesartan. Hypertension 2008, 51:296-301.
23. Forstermann U., Munzel T. Endothelial nitric oxide synthase in vascular disease: from marvel to menace. Circulation 2006, 113:1708-1714.
24. Kim J.A., Montagnani M., Koh K.K., Quon M.J. Reciprocal relationships between insulin resistance and endothelial dysfunction: molecular and pathophysiological mechanisms. Circulation 2006, 113:1888-1904.